Cargando…

Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α

BACKGROUND: A novel pattern in the indirect immunofluorescence antinuclear antibody assay on HEp-2 cells (IIF-HEp-2) characterized by cytoplasmic rods and rings (RR) was reported in HCV patients, but stringent disease specificity studies and longitudinal analysis are lacking. We investigated the cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keppeke, Gerson Dierley, Nunes, Eunice, Ferraz, Maria Lucia Gomes, Silva, Eduardo Antônio Benedito, Granato, Celso, Chan, Edward K. L., Andrade, Luís Eduardo C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454395/ https://www.ncbi.nlm.nih.gov/pubmed/23028980 http://dx.doi.org/10.1371/journal.pone.0045392

Ejemplares similares

Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures
por: Keppeke, Gerson Dierley, et al.
Publicado: (2015)

Anti-Rods/Rings: A Human Model of Drug-Induced Autoantibody Generation
por: Calise, S. John, et al.
Publicado: (2015)

A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation
por: Keppeke, Gerson Dierley, et al.
Publicado: (2022)

Effect on cell survival and cytoophidium assembly of the adRP-10-related IMPDH1 missense mutation Asp226Asn
por: Keppeke, Gerson Dierley, et al.
Publicado: (2023)

The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection
por: Afsharzadeh, Fatemeh, et al.
Publicado: (2016)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

IMP/GTP balance modulates cytoophidium assembly and IMPDH activity
por: Keppeke, Gerson Dierley, et al.
Publicado: (2018)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Anti-Rods and Rings Autoantibodies in a Patient With Hepatitis C Virus Infection
por: Choi, Kyung Ho, et al.
Publicado: (2015)

Anti-rods and rings autoantibodies can occur in the hepatitis c-naïve population
por: SHAIKH, Y., et al.
Publicado: (2013)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience
por: Kozielewicz, D., et al.
Publicado: (2011)

Presence of HCV RNA in peripheral blood mononuclear cells may predict patients’ response to interferon and ribavirin therapy
por: Zaman, Nasib, et al.
Publicado: (2014)

Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
por: Assandri, Roberto, et al.
Publicado: (2021)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Psychological characteristics of caregivers of pediatric patients with chronic rheumatic disease in relation to treatment adherence
por: Keppeke, Livia de Freitas, et al.
Publicado: (2018)

Long-term antiviral hepatitis C treatment associated with Rods and Ring Cytoplasmic antibodies
por: Feldrihan, Vasile, et al.
Publicado: (2019)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Induction of Cytoplasmic Rods and Rings Structures by Inhibition of the CTP and GTP Synthetic Pathway in Mammalian Cells
por: Carcamo, Wendy C., et al.
Publicado: (2011)

U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients
por: Ho, Samuel B., et al.
Publicado: (2011)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation
por: Panigrahi, Rajesh, et al.
Publicado: (2013)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
por: Zhang, Geng-lin, et al.
Publicado: (2017)

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
por: Malaguarnera, Giulia, et al.
Publicado: (2016)

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
por: Kawaguchi, Takumi, et al.
Publicado: (2019)

Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37
por: Ding, Shi-xiong, et al.
Publicado: (2016)

The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C
por: Wasmuth, Hermann E, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_potoma3jv62l7thlg24aidjml7